We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+32.7%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.21B
AUM Growth
+$566M
Cap. Flow
+$396M
Cap. Flow %
32.65%
Top 10 Hldgs %
61.2%
Holding
106
New
26
Increased
22
Reduced
28
Closed
20

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$20.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19M
3
NVS icon
Novartis
NVS
+$17.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$11.6M
5
NVO
Novo Nordisk
NVO
+$10.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.8M
2
ARQL
Arqule Inc
ARQL
+$20.7M
3
GILD icon
Gilead Sciences
GILD
+$13.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$11.2M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 52.36%
2 Technology 6.25%
3 Industrials 0.98%
4 Consumer Discretionary 0.93%
5 Communication Services 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$266M 21.95%
+2,800,000
New +$242M
IBB icon
2
PUT
iShares Biotechnology ETF
IBB
$9.34B
$121M 9.93%
+1,000,000
New +$112M
JNJ icon
3
Johnson & Johnson
JNJ
$618B
$64M 5.27%
438,653
+38,653
+10% +$5.24M
BMY icon
4
Bristol-Myers Squibb
BMY
$133B
$58.7M 4.84%
915,000
-194,900
-18% -$11.2M
SNY icon
5
Sanofi
SNY
$103B
$57.2M 4.72%
1,140,000
+440,000
+63% +$20.6M
MRK icon
6
Merck
MRK
$322B
$50.5M 4.16%
581,640
+89,080
+18% +$7.32M
NVO
7
Novo Nordisk
NVO
$208B
$37M 3.05%
1,280,000
+380,000
+42% +$10.5M
GILD icon
8
CALL
Gilead Sciences
GILD
$162B
$32.5M 2.68%
500,000
– –
SGEN
9
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$28.6M 2.35%
+250,000
New +$26.5M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$27.3M 2.25%
2,800,320
-130,000
-4% -$1.19M
BMRN icon
11
BioMarin Pharmaceuticals
BMRN
$11.6B
$21.3M 1.75%
+251,382
New +$19M
NVS icon
12
Novartis
NVS
$297B
$18.9M 1.56%
+200,000
New +$17.9M
SRPT icon
13
Sarepta Therapeutics
SRPT
$1.57B
$18.1M 1.49%
140,000
-108,038
-44% -$10.9M
VRNT
14
DELISTED
Verint Systems
VRNT
$16.1M 1.33%
570,642
+306,640
+116% +$7.47M
ACAD icon
15
Acadia Pharmaceuticals
ACAD
$4.43B
$15.3M 1.26%
357,000
+267,000
+297% +$11.6M
ALXN
16
DELISTED
Alexion Pharmaceuticals
ALXN
$12.5M 1.03%
115,713
-50,000
-30% -$5.35M
TEVA icon
17
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$12M 0.99%
1,220,600
-329,400
-21% -$2.94M
VTRS icon
18
Viatris
VTRS
$20.4B
$11.3M 0.93%
+560,000
New +$10.4M
PTCT icon
19
PTC Therapeutics
PTCT
$5.68B
$10.3M 0.85%
214,736
-95,264
-31% -$4.05M
ASND icon
20
Ascendis Pharma A/S
ASND
$16B
$10.3M 0.85%
73,773
– –
QURE icon
21
uniQure
QURE
$3.03B
$10M 0.82%
139,514
-37,986
-21% -$2.09M
MSFT icon
22
Microsoft
MSFT
$3.45T
$9.26M 0.76%
58,741
+5,000
+9% +$735K
BPMC
23
DELISTED
Blueprint Medicines
BPMC
$8.49M 0.7%
106,000
+63,500
+149% +$4.75M
XCUR icon
24
Exicure
XCUR
$10.2M
$8.26M 0.68%
19,259
+1,672
+10% +$684K
ALLT icon
25
Allot
ALLT
$372M
$8.25M 0.68%
970,666
+309,635
+47% +$2.54M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2019 Portfolio in Review

As of Q4 2019, Sphera Funds Management held 106 positions worth $1.21B, up 87% from $647M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sphera Funds Management deployed $396M of net new capital in Q4 2019, opening 26 new positions and adding to 22 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 74% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Arqule Inc, an estimated $20.7M trimmed.

  • Sphera Funds Management's largest Q4 2019 buy was BioMarin Pharmaceuticals: 251,382 shares worth $21.3M.
  • Sphera Funds Management added most to Sanofi in Q4 2019, an estimated $20.6M increase.
  • Sphera Funds Management's biggest Q4 2019 reduction was Arqule Inc, cutting an estimated $20.7M.
  • Sphera Funds Management fully exited Celgene Corp in Q4 2019, selling an estimated $24.8M.
  • Sphera Funds Management's ten largest holdings make up 61% of its $1.21B portfolio in Q4 2019.
  • Sphera Funds Management opened 26 new positions and closed 20 in Q4 2019.
  • Sphera Funds Management's portfolio value rose 87% quarter-over-quarter to $1.21B.

Based on Sphera Funds Management's 13F filing for Q4 2019, filed 13 Feb 2020.